Barclays’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25K | Sell |
20,925
-11,773
| -36% | -$14.1K | ﹤0.01% | 4053 |
|
|
2025
Q1 | $66K | Sell |
32,698
-5,393
| -14% | -$10.9K | ﹤0.01% | 3812 |
|
|
2024
Q4 | $228K | Buy |
38,091
+4,785
| +14% | +$28.6K | ﹤0.01% | 3456 |
|
|
2024
Q3 | $233K | Buy |
33,306
+11,273
| +51% | +$78.9K | ﹤0.01% | 3405 |
|
|
2024
Q2 | $127K | Buy |
22,033
+709
| +3% | +$4.09K | ﹤0.01% | 3262 |
|
|
2024
Q1 | $153K | Sell |
21,324
-3,160
| -13% | -$22.7K | ﹤0.01% | 3462 |
|
|
2023
Q4 | $121K | Buy |
24,484
+10,384
| +74% | +$51.3K | ﹤0.01% | 3669 |
|
|
2023
Q3 | $135K | Sell |
14,100
-163
| -1% | -$1.56K | ﹤0.01% | 3205 |
|
|
2023
Q2 | $184K | Sell |
14,263
-2,720
| -16% | -$35.1K | ﹤0.01% | 3126 |
|
|
2023
Q1 | $215K | Buy |
16,983
+12,841
| +310% | +$163K | ﹤0.01% | 3105 |
|
|
2022
Q4 | $47K | Buy |
+4,142
| New | +$47K | ﹤0.01% | 3793 |
|